Oxford Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Oxford Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26,151	Closed	-$134K	–	1497
2019 Q4	$134K	Buy	+26,151	New	+$145K	﹤0.01%	1599
2018 Q1	–	Sell	-140,877	Closed	-$5.92M	–	1959
2017 Q4	$5.92M	Buy	140,877 +32,148	+30%	+$1.44M	0.13%	187
2017 Q3	$5.84M	Buy	108,729 +97,188	+842%	+$16.4M	0.11%	188
2017 Q2	$2.14M	Buy	+11,541	New	+$2.02M	0.04%	579

Other funds holding SIOX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oxford Asset Management's SIOX Position: Q1 2020 in Review

Oxford Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 26,151 shares — an estimated $134K sold.

Oxford Asset Management first reported a position in SIOX in Q2 2017 and held it in 4 quarters. The position peaked at $5.92M in Q4 2017. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

Oxford Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 26,151 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $134K.
Oxford Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Oxford Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $5.92M in Q4 2017.
42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.